Lipogen’s Natural Formula Clinically Proven To Reduce PMS Symptoms

Friday, May 4th, 2018 | 630 Views

A new clinical study has confirmed the positive effects of Lipogen PMS, a natural phospholipid formulation, in treating and relieving premenstrual syndrome (PMS) symptoms. PMS is defined as physical and/or emotional symptoms that occur one or two weeks before a woman’s period.

A randomised, double-blind, placebo-controlled clinical study was directed by Juliane Hellhammer, PhD, the chief executive officer of daacro GmbH & Company KG, a contract research organisation in Trier, Germany. The research, published in Clinical Nutrition ESPEN in February 2018, evaluated 40 women aged 18-45 who were diagnosed with PMS by their physicians.

The product treatment group experienced an ongoing reduction in PMS symptoms, while the placebo group returned to initial PMS symptom levels. Dr Hellhammer says: “I am quite impressed that a natural, non-pharmaceutical product has promising potential for relieving women’s PMS symptoms.”

The study observed women during an initial baseline menstrual cycle followed by three menstrual cycles in which subjects received daily treatment of the Lipogen PMS complex of 400 mg phosphatidylserine (PS) and 400 mg phosphatidic acid (PA). Treatment compliance was monitored with an electronic medication event monitoring system (MEMS).

Using the standardised Daily Record of Severity of Problems scale, the study showed Lipogen PMS improved symptoms in the four primary measures (p=o.001):

Emotional Relief: the product demonstrated relief from emotional responses—reducing depression and levelling out mood swings.

Physical Relief: Women taking the product experienced reduced physical symptoms, such as lowered fatigue, decreased bloating, less appetite disturbances and fewer sleep problems. The level of their stress hormone—cortisol—also decreased.

Cognitive Relief: the product lowered the impact of PMS on productivity.

Social Relief: PMS sufferers who took the product experienced less interference in relationships.

Lipogen PMS, patented in the US, Europe and Japan, is all-natural and has earned both US FDA GRAS status and EU EFSA Novel Food Approval. Lipogen is considering to further develop the product as a botanical drug.

According to the American Family Physician Journal, 20 to 30 percent of women of child-bearing age experience PMS, while premenstrual dysphoric disorder affects three to eight percent of pre-menstrual women.

The latest research published by Credence Research reported that the global PMS treatment market was valued at US$4.2 billion in 2015, and is expected to reach US$5 billion by 2024—expanding at a compound annual growth rate of two percent from 2016 to 2024.

“This research in relieving women’s PMS symptoms is relevant to a large segment of the population,” says David Rutenberg, chief executive officer for Lipogen.

“The new Lipogen PMS product may help women as a natural solution for controlling PMS symptoms,” Rutenberg adds.